Anti-PIP5K3 monoclonal antibody
Pre-made anti-PIP5K3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to PIP5K3/PIKFYVE products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T02469-Ab-1/ GM-Tg-hg-T02469-Ab-2 | Anti-Human PIP5K3/PIKFYVE monoclonal antibody | Human |
GM-Tg-rg-T02469-Ab-1/ GM-Tg-rg-T02469-Ab-2 | Anti-Rat PIP5K3/PIKFYVE monoclonal antibody | Rat |
GM-Tg-mg-T02469-Ab-1/ GM-Tg-mg-T02469-Ab-2 | Anti-Mouse PIP5K3/PIKFYVE monoclonal antibody | Mouse |
GM-Tg-cynog-T02469-Ab-1/ GM-Tg-cynog-T02469-Ab-2 | Anti-Cynomolgus/ Rhesus macaque PIP5K3/PIKFYVE monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T02469-Ab-1/ GM-Tg-felg-T02469-Ab-2 | Anti-Feline PIP5K3/PIKFYVE monoclonal antibody | Feline |
GM-Tg-cang-T02469-Ab-1/ GM-Tg-cang-T02469-Ab-2 | Anti-Canine PIP5K3/PIKFYVE monoclonal antibody | Canine |
GM-Tg-bovg-T02469-Ab-1/ GM-Tg-bovg-T02469-Ab-2 | Anti-Bovine PIP5K3/PIKFYVE monoclonal antibody | Bovine |
GM-Tg-equg-T02469-Ab-1/ GM-Tg-equg-T02469-Ab-2 | Anti-Equine PIP5K3/PIKFYVE monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T02469-Ab-1/ GM-Tg-hg-T02469-Ab-2; GM-Tg-rg-T02469-Ab-1/ GM-Tg-rg-T02469-Ab-2; GM-Tg-mg-T02469-Ab-1/ GM-Tg-mg-T02469-Ab-2; GM-Tg-cynog-T02469-Ab-1/ GM-Tg-cynog-T02469-Ab-2; GM-Tg-felg-T02469-Ab-1/ GM-Tg-felg-T02469-Ab-2; GM-Tg-cang-T02469-Ab-1/ GM-Tg-cang-T02469-Ab-2; GM-Tg-bovg-T02469-Ab-1/ GM-Tg-bovg-T02469-Ab-2; GM-Tg-equg-T02469-Ab-1/ GM-Tg-equg-T02469-Ab-2 |
Products Name | Anti-PIP5K3/PIKFYVE monoclonal antibody |
Format | mab |
Target Name | PIP5K3 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-PIP5K3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T02469-Ag-1 | Recombinant multi-species FYV1/ PIP5K3/ PIKFYVE protein |
Target information
Target ID | GM-T02469 |
Target Name | PIP5K3 |
Gene ID | 200576,18711,316457,710115,478890,101094121,790873,100066445 |
Gene Symbol and Synonyms | 5230400C17Rik,CFD,FAB1,fab1-like,HEL37,p235,PIKFYVE,PIP5K,PIP5K3,Pipk5k3,PipkIII,ZFYVE29 |
Uniprot Accession | Q9Y2I7 |
Uniprot Entry Name | FYV1_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000115020 |
Target Classification | Kinase |
The target: PIP5K3, gene name: PIKFYVE, also named as CFD, FAB1, HEL37, PIP5K, PIP5K3, ZFYVE29. Phosphorylated derivatives of phosphatidylinositol (PtdIns) regulate cytoskeletal functions, membrane trafficking, and receptor signaling by recruiting protein complexes to cell- and endosomal-membranes. Humans have multiple PtdIns proteins that differ by the degree and position of phosphorylation of the inositol ring. This gene encodes an enzyme (PIKfyve; also known as phosphatidylinositol-3-phosphate 5-kinase type III or PIPKIII) that phosphorylates the D-5 position in PtdIns and phosphatidylinositol-3-phosphate (PtdIns3P) to make PtdIns5P and PtdIns(3,5)biphosphate. The D-5 position also can be phosphorylated by type I PtdIns4P-5-kinases (PIP5Ks) that are encoded by distinct genes and preferentially phosphorylate D-4 phosphorylated PtdIns. In contrast, PIKfyve preferentially phosphorylates D-3 phosphorylated PtdIns. In addition to being a lipid kinase, PIKfyve also has protein kinase activity. PIKfyve regulates endomembrane homeostasis and plays a role in the biogenesis of endosome carrier vesicles from early endosomes. The protein plays a key role in cell entry of ebola virus and SARS-CoV-2 by endocytosis Mutations in this gene cause corneal fleck dystrophy (CFD); an autosomal dominant disorder characterized by numerous small white flecks present in all layers of the corneal stroma. Histologically, these flecks appear to be keratocytes distended with lipid and mucopolysaccharide filled intracytoplasmic vacuoles. [provided by RefSeq, Jul 2021].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.